Opinion|Videos|December 3, 2024
Understanding PIRA in MS: Key Insights and Advances From ECTRIMS 2024
Author(s)Gabriel Pardo, MD, FAAN, Martin Belkin, DO
Key Takeaways
- PIRA represents MS progression without clinical relapses, impacting patients' quality of life by contributing to disability accumulation.
- Unlike RAW, PIRA reflects insidious progression, often undetected by traditional relapse-focused assessments.
Panelists discuss how progression independent of relapse activity (PIRA) in multiple sclerosis (MS) represents continuous neurological decline unrelated to inflammatory events, distinct from relapse-associated worsening (RAW). Recent ECTRIMS 2024 presentations emphasized standardized evaluation methods to better understand disease progression and improve patient management strategies.
Advertisement
Video content above is prompted by the following:
- Cognition and PIRA in MS have received a lot of attention in recent years.
- Please provide an overview of PIRA and its potential impact on a patient’s quality of life.
- How is PIRA different from RAW?
- How is PIRA evaluated? Discuss presentations from ECTRIMS 2024 by Muller and others about standardization of PIRA evaluation and why it might matter.
Advertisement
Related to this article
A recent MS cohort study suggests that higher EBV nuclear antigen 1 antibody levels are associated with a lower risk of confirmed disability worsening, particularly among patients carrying both HLA-A02:01 and HLA-DRB115:01.
Xenon Pharmaceuticals submitted an FDA New Drug Application for azetukalner, a KV7 potassium channel opener, as adjunctive therapy for focal seizures in epilepsy.
The CHMP recommended approval of gefurulimab (Klygefa), a weekly self-administered C5 inhibitor, for AChR-antibody-positive generalized myasthenia gravis in the EU.
Here's some of what is coming soon to NeurologyLive® this week.
Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is Parkinson disease biomarkers!
A retrospective cohort study found DTI-ALPS, a glymphatic function marker, did not independently predict survival in glioblastoma beyond extent of resection and sex.
The approval, based on phase 3 IB1001-303 trial data showing consistent SARA scale improvement, makes levacetylleucine the first treatment approved specifically for ataxia-telangiectasia.
Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending September 18, 2026.
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
Gefurulimab Recommended for EU Approval in Generalized Myasthenia Gravis
2
FDA Approves Levacetylleucine for Ataxia-Telangiectasia
3
Episode 175: Advancing the Ways of Treating Cluster Headache
4
Xenon Submits New Drug Application for Azetukalner as Treatment for Focal Seizures
5